{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:28:44Z","timestamp":1795044524945,"version":"4.10.2"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1038\/s41569-025-01187-2","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T23:07:45Z","timestamp":1753139265000},"page":"675-688","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["European guidelines for hypertension in 2024: a comparison of key recommendations for clinical practice"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1434-9556","authenticated-orcid":false,"given":"Lucas","family":"Lauder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6107-3356","authenticated-orcid":false,"given":"Rosa Maria","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gerdts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhold","family":"Kreutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"L\u00fcscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Mancia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John William","family":"McEvoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"McManus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0851-7675","authenticated-orcid":false,"given":"Mpiko","family":"Ntsekhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9402-7439","authenticated-orcid":false,"given":"Gianfranco","family":"Parati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1888-5842","authenticated-orcid":false,"given":"Rosa","family":"de Pinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4807-4610","authenticated-orcid":false,"given":"Kazem","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9174-4018","authenticated-orcid":false,"given":"Pantelis","family":"Sarafidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9217-4937","authenticated-orcid":false,"given":"Aletta E.","family":"Schutte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0670-0887","authenticated-orcid":false,"given":"Rhian M.","family":"Touyz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4425-549X","authenticated-orcid":false,"given":"Felix","family":"Mahfoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"1187_CR1","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa2206916","volume":"389","author":"C Magnussen","year":"2023","unstructured":"Magnussen, C. et al. Global effect of modifiable risk factors on cardiovascular disease and mortality. N. Engl. J. Med. 389, 1273\u20131285 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1187_CR2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","volume":"398","author":"NCD Risk Factor Collaboration (NCD-RisC).","year":"2021","unstructured":"NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 398, 957\u2013980 (2021).","journal-title":"Lancet"},{"key":"1187_CR3","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy, J. W. et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur. Heart J. 45, 3912\u20134018 (2024).","journal-title":"Eur. Heart J."},{"key":"1187_CR4","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia, G. et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J. Hypertens. 41, 1874\u20132071 (2023).","journal-title":"J. Hypertens."},{"key":"1187_CR5","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","volume":"360","author":"S Lewington","year":"2002","unstructured":"Lewington, S. et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903\u20131913 (2002).","journal-title":"Lancet"},{"key":"1187_CR6","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1001\/jamacardio.2020.1731","volume":"5","author":"SP Whelton","year":"2020","unstructured":"Whelton, S. P. et al. Association of normal systolic blood pressure level with cardiovascular disease in the absence of risk factors. JAMA Cardiol. 5, 1011\u20131018 (2020).","journal-title":"JAMA Cardiol."},{"key":"1187_CR7","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1161\/CIRCULATIONAHA.120.049819","volume":"143","author":"M Arvanitis","year":"2021","unstructured":"Arvanitis, M. et al. Linear and nonlinear Mendelian randomization analyses of the association between diastolic blood pressure and cardiovascular events: the J-curve revisited. Circulation 143, 895\u2013906 (2021).","journal-title":"Circulation"},{"key":"1187_CR8","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","volume":"383","author":"E Rapsomaniki","year":"2014","unstructured":"Rapsomaniki, E. et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 383, 1899\u20131911 (2014).","journal-title":"Lancet"},{"key":"1187_CR9","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1161\/HYPERTENSIONAHA.120.16534","volume":"77","author":"R Malik","year":"2021","unstructured":"Malik, R. et al. Relationship between blood pressure and incident cardiovascular disease: linear and nonlinear mendelian randomization analyses. Hypertension 77, 2004\u20132013 (2021).","journal-title":"Hypertension"},{"key":"1187_CR10","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams, B. et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur. Heart J. 39, 3021\u20133104 (2018).","journal-title":"Eur. Heart J."},{"key":"1187_CR11","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJM199704173361601","volume":"336","author":"LJ Appel","year":"1997","unstructured":"Appel, L. J. et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH collaborative research group. N. Engl. J. Med. 336, 1117\u20131124 (1997).","journal-title":"N. Engl. J. Med."},{"key":"1187_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-207","volume":"11","author":"E Toledo","year":"2013","unstructured":"Toledo, E. et al. Effect of the Mediterranean diet on blood pressure in the PREDIMED trial: results from a randomized controlled trial. BMC Med. 11, 207 (2013).","journal-title":"BMC Med."},{"key":"1187_CR13","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/HJH.0000000000000881","volume":"34","author":"C Thomopoulos","year":"2016","unstructured":"Thomopoulos, C., Parati, G. & Zanchetti, A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels\u00a0\u2014 updated overview and meta-analyses of randomized trials. J. Hypertens. 34, 613\u2013622 (2016).","journal-title":"J. Hypertens."},{"key":"1187_CR14","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S0140-6736(14)61212-5","volume":"384","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration.","year":"2014","unstructured":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 384, 591\u2013598 (2014).","journal-title":"Lancet"},{"key":"1187_CR15","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1097\/HJH.0000000000000380","volume":"32","author":"C Thomopoulos","year":"2014","unstructured":"Thomopoulos, C., Parati, G. & Zanchetti, A. Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk-overview and meta-analyses of randomized trials. J. Hypertens. 32, 2305\u20132314 (2014).","journal-title":"J. Hypertens."},{"key":"1187_CR16","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1097\/HJH.0000000000003483","volume":"41","author":"GS Stergiou","year":"2023","unstructured":"Stergiou, G. S. et al. European society of hypertension recommendations for the validation of cuffless blood pressure measuring devices: European society of hypertension working group on blood pressure monitoring and cardiovascular variability. J. Hypertens. 41, 2074\u20132087 (2023).","journal-title":"J. Hypertens."},{"key":"1187_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-072112","volume":"380","author":"C Crump","year":"2023","unstructured":"Crump, C. et al. Adverse pregnancy outcomes and long term risk of ischemic heart disease in mothers: national cohort and co-sibling study. BMJ 380, e072112 (2023).","journal-title":"BMJ"},{"key":"1187_CR18","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","volume":"69","author":"S Monticone","year":"2017","unstructured":"Monticone, S. et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J. Am. Coll. Cardiol. 69, 1811\u20131820 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1187_CR19","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1016\/j.jacc.2019.09.057","volume":"74","author":"GP Rossi","year":"2019","unstructured":"Rossi, G. P. Primary aldosteronism: JACC state-of-the-art review. J. Am. Coll. Cardiol. 74, 2799\u20132811 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1187_CR20","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1097\/HJH.0000000000002510","volume":"38","author":"P Mulatero","year":"2020","unstructured":"Mulatero, P. et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J. Hypertens. 38, 1919\u20131928 (2020).","journal-title":"J. Hypertens."},{"key":"1187_CR21","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1097\/HJH.0000000000002520","volume":"38","author":"P Mulatero","year":"2020","unstructured":"Mulatero, P. et al. Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J. Hypertens. 38, 1929\u20131936 (2020).","journal-title":"J. Hypertens."},{"key":"1187_CR22","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"Sprint Research Group.","year":"2015","unstructured":"Sprint Research Group. A Randomized trial of intensive versus standard blood-pressure control. N. Engl. J. Med. 373, 2103\u20132116 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1187_CR23","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"ACCORD Study Group","year":"2010","unstructured":"ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575\u20131585 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1187_CR24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(24)01028-6","volume":"404","author":"J Liu","year":"2024","unstructured":"Liu, J. et al. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet 404, 245\u2013255 (2024).","journal-title":"Lancet"},{"key":"1187_CR25","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","volume":"397","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration.","year":"2021","unstructured":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet 397, 1625\u20131636 (2021).","journal-title":"Lancet"},{"key":"1187_CR26","doi-asserted-by":"publisher","first-page":"3S","DOI":"10.1016\/S0895-7061(99)00252-6","volume":"13","author":"WB Kannel","year":"2000","unstructured":"Kannel, W. B. Risk stratification in hypertension: new insights from the Framingham study. Am. J. Hypertens. 13, 3S\u201310S (2000).","journal-title":"Am. J. Hypertens."},{"key":"1187_CR27","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.amjhyper.2006.10.013","volume":"20","author":"D Weycker","year":"2007","unstructured":"Weycker, D. et al. Risk-factor clustering and cardiovascular disease risk in hypertensive patients. Am. J. Hypertens. 20, 599\u2013607 (2007).","journal-title":"Am. J. Hypertens."},{"key":"1187_CR28","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ijcard.2020.09.053","volume":"325","author":"CCV Klooster","year":"2021","unstructured":"Klooster, C. C. V. et al. Predicting 10-year risk of recurrent cardiovascular events andcardiovascular interventions in patients with established cardiovascular disease: results from UCC-SMART and REACH. Int. J. Cardiol. 325, 140\u2013148 (2021).","journal-title":"Int. J. Cardiol."},{"key":"1187_CR29","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1161\/CIRCULATIONAHA.116.021314","volume":"134","author":"L Kaasenbrood","year":"2016","unstructured":"Kaasenbrood, L. et al. Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population. Circulation 134, 1419\u20131429 (2016).","journal-title":"Circulation"},{"key":"1187_CR30","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/eurjhf\/hfr170","volume":"14","author":"CJ Taylor","year":"2012","unstructured":"Taylor, C. J., Roalfe, A. K., Iles, R. & Hobbs, F. D. Ten-year prognosis of heart failure in the community: follow-up data from the Echocardiographic Heart of England Screening (ECHOES) study. Eur. J. Heart Fail. 14, 176\u2013184 (2012).","journal-title":"Eur. J. Heart Fail."},{"key":"1187_CR31","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","volume":"70","author":"KS Shah","year":"2017","unstructured":"Shah, K. S. et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J. Am. Coll. Cardiol. 70, 2476\u20132486 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1187_CR32","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","volume":"98","author":"EJ Benjamin","year":"1998","unstructured":"Benjamin, E. J. et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98, 946\u2013952 (1998).","journal-title":"Circulation"},{"key":"1187_CR33","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s00125-008-1076-y","volume":"51","author":"HE Mulnier","year":"2008","unstructured":"Mulnier, H. E. et al. Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using the general practice research database. Diabetologia 51, 1639\u20131645 (2008).","journal-title":"Diabetologia"},{"key":"1187_CR34","doi-asserted-by":"publisher","first-page":"798","DOI":"10.2337\/diacare.29.04.06.dc05-1433","volume":"29","author":"SS Soedamah-Muthu","year":"2006","unstructured":"Soedamah-Muthu, S. S. et al. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care 29, 798\u2013804 (2006).","journal-title":"Diabetes Care"},{"key":"1187_CR35","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1161\/ATVBAHA.121.316106","volume":"41","author":"M Paquette","year":"2021","unstructured":"Paquette, M. et al. Familial hypercholesterolemia-risk-score: a new score predicting cardiovascular events and cardiovascular mortality in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 41, 2632\u20132640 (2021).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1187_CR36","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1161\/HYPERTENSIONAHA.121.18502","volume":"79","author":"RS Vasan","year":"2022","unstructured":"Vasan, R. S. et al. Hypertension-mediated organ damage: prevalence, correlates, and prognosis in the community. Hypertension 79, 505\u2013515 (2022).","journal-title":"Hypertension"},{"key":"1187_CR37","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1161\/CIRCULATIONAHA.120.052430","volume":"144","author":"AP Patel","year":"2021","unstructured":"Patel, A. P., Wang, M., Kartoun, U., Ng, K. & Khera, A. V. Quantifying and understanding the higher risk of atherosclerotic cardiovascular disease among south asian individuals: results from the UK biobank prospective cohort study. Circulation 144, 410\u2013422 (2021).","journal-title":"Circulation"},{"key":"1187_CR38","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ypmed.2014.04.007","volume":"64","author":"G Veronesi","year":"2014","unstructured":"Veronesi, G. et al. Improving long-term prediction of first cardiovascular event: the contribution of family history of coronary heart disease and social status. Prev. Med. 64, 75\u201380 (2014).","journal-title":"Prev. Med."},{"key":"1187_CR39","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.122.060042","volume":"146","author":"DM Kimenai","year":"2022","unstructured":"Kimenai, D. M. et al. Socioeconomic deprivation: an important, largely unrecognized risk factor in primary prevention of cardiovascular disease. Circulation 146, 240\u2013248 (2022).","journal-title":"Circulation"},{"key":"1187_CR40","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(22)01349-6","volume":"400","author":"N Conrad","year":"2022","unstructured":"Conrad, N. et al. Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet 400, 733\u2013743 (2022).","journal-title":"Lancet"},{"key":"1187_CR41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/wps.20420","volume":"16","author":"CU Correll","year":"2017","unstructured":"Correll, C. U. et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 16, 163\u2013180 (2017).","journal-title":"World Psychiatry"},{"key":"1187_CR42","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","volume":"138","author":"ASV Shah","year":"2018","unstructured":"Shah, A. S. V. et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis. Circulation 138, 1100\u20131112 (2018).","journal-title":"Circulation"},{"key":"1187_CR43","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1016\/j.jacc.2019.09.052","volume":"74","author":"MC Honigberg","year":"2019","unstructured":"Honigberg, M. C. et al. Long-term cardiovascular risk in women with hypertension during pregnancy. J. Am. Coll. Cardiol. 74, 2743\u20132754 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1187_CR44","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00125-019-4840-2","volume":"62","author":"CK Kramer","year":"2019","unstructured":"Kramer, C. K., Campbell, S. & Retnakaran, R. Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis. Diabetologia 62, 905\u2013914 (2019).","journal-title":"Diabetologia"},{"key":"1187_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oeac065","volume":"2","author":"H Kyriacou","year":"2022","unstructured":"Kyriacou, H. et al. The risk of cardiovascular diseases after miscarriage, stillbirth, and induced abortion: a systematic review and meta-analysis. Eur. Heart J. Open\u00a02, oeac065 (2022).","journal-title":"Eur. Heart J. Open"},{"key":"1187_CR46","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1056\/NEJMoa1600175","volume":"374","author":"EM Lonn","year":"2016","unstructured":"Lonn, E. M. et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N. Engl. J. Med. 374, 2009\u20132020 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1187_CR47","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1093\/eurheartj\/ehab225","volume":"42","author":"J Bosch","year":"2021","unstructured":"Bosch, J. et al. Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of heart outcomes evaluation prevention (HOPE)-3 study participants. Eur. Heart J. 42, 2995\u20133007 (2021).","journal-title":"Eur. Heart J."},{"key":"1187_CR48","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1161\/HYPERTENSIONAHA.121.18413","volume":"79","author":"M Brunstr\u00f6m","year":"2022","unstructured":"Brunstr\u00f6m, M., Thomopoulos, C., Carlberg, B., Kreutz, R. & Mancia, G. Methodological aspects of meta-analyses assessing the effect of blood pressure-lowering treatment on clinical outcomes. Hypertension 79, 491\u2013504 (2022).","journal-title":"Hypertension"},{"key":"1187_CR49","doi-asserted-by":"publisher","first-page":"2430228","DOI":"10.1080\/08037051.2024.2430228","volume":"33","author":"SE Kjeldsen","year":"2024","unstructured":"Kjeldsen, S. E. et al. Should treatment of \u2018elevated\u2019 blood pressure, especially in older people, be based on global risk estimation? Blood Press. 33, 2430228 (2024).","journal-title":"Blood Press."},{"key":"1187_CR50","doi-asserted-by":"publisher","first-page":"184","DOI":"10.7326\/M14-0773","volume":"162","author":"J Sundstr\u00f6m","year":"2015","unstructured":"Sundstr\u00f6m, J. et al. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann. Intern. Med. 162, 184\u2013191 (2015).","journal-title":"Ann. Intern. Med."},{"key":"1187_CR51","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad, D. et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387, 957\u2013967 (2016).","journal-title":"Lancet"},{"key":"1187_CR52","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1161\/HYPERTENSIONAHA.123.21496","volume":"80","author":"Z Bidel","year":"2023","unstructured":"Bidel, Z. et al. Sex-specific effects of blood pressure lowering pharmacotherapy for the prevention of cardiovascular disease: an individual participant-level data meta-analysis. Hypertension 80, 2293\u20132302 (2023).","journal-title":"Hypertension"},{"key":"1187_CR53","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1161\/CIRCULATIONAHA.120.049360","volume":"143","author":"H Ji","year":"2021","unstructured":"Ji, H. et al. Sex differences in blood pressure associations with cardiovascular outcomes. Circulation 143, 761\u2013763 (2021).","journal-title":"Circulation"},{"key":"1187_CR54","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/eurjpc\/zwab068","volume":"29","author":"E Kringeland","year":"2022","unstructured":"Kringeland, E. et al. Stage 1 hypertension, sex, and acute coronary syndromes during midlife: the Hordaland health study. Eur. J. Prev. Cardiol. 29, 147\u2013154 (2022).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"1187_CR55","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","volume":"42","author":"SCORE2 working group and ESC Cardiovascular risk collaboration.","year":"2021","unstructured":"SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur. Heart J. 42, 2439\u20132454 (2021).","journal-title":"Eur. Heart J."},{"key":"1187_CR56","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1093\/eurheartj\/ehab312","volume":"42","author":"SCORE2-OP working group and ESC Cardiovascular risk collaboration.","year":"2021","unstructured":"SCORE2-OP working group and ESC Cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur. Heart J. 42, 2455\u20132467 (2021).","journal-title":"Eur. Heart J."},{"key":"1187_CR57","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11906-024-01311-6","volume":"26","author":"M Barozet","year":"2024","unstructured":"Barozet, M., Le Tilly, O., Bejan-Angoulvant, T., Fesler, P. & Roubille, C. Hypertension and cardiovascular outcomes in inflammatory and autoimmune diseases: a systematic review and meta-analysis. Curr. Hypertens. Rep. 26, 419\u2013429 (2024).","journal-title":"Curr. Hypertens. Rep."},{"key":"1187_CR58","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1001\/jamacardio.2019.1746","volume":"4","author":"EB Haug","year":"2019","unstructured":"Haug, E. B. et al. Association of conventional cardiovascular risk factors with cardiovascular disease after hypertensive disorders of pregnancy: analysis of the Nord-Trondelag health study. JAMA Cardiol. 4, 628\u2013635 (2019).","journal-title":"JAMA Cardiol."},{"key":"1187_CR59","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1681\/ASN.0000000539","volume":"36","author":"A Sarwal","year":"2024","unstructured":"Sarwal, A. et al. Baseline diastolic BP and BP-lowering effects on cardiovascular outcomes and all-cause mortality: a meta-analysis. J. Am. Soc. Nephrol. 36, 911\u2013922 (2024).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1187_CR60","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1161\/HYPERTENSIONAHA.122.20489","volume":"80","author":"S Rao","year":"2023","unstructured":"Rao, S. et al. Systolic blood pressure and cardiovascular risk in patients with diabetes: a prospective cohort study. Hypertension 80, 598\u2013607 (2023).","journal-title":"Hypertension"},{"key":"1187_CR61","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","volume":"385","author":"W Zhang","year":"2021","unstructured":"Zhang, W. et al. Trial of intensive blood-pressure control in older patients with hypertension. N. Engl. J. Med. 385, 1268\u20131279 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1187_CR62","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S0140-6736(09)61340-4","volume":"374","author":"P Verdecchia","year":"2009","unstructured":"Verdecchia, P. et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 374, 525\u2013533 (2009).","journal-title":"Lancet"},{"key":"1187_CR63","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(13)60852-1","volume":"382","author":"SPS3 Study Group.","year":"2013","unstructured":"SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 382, 507\u2013515 (2013).","journal-title":"Lancet"},{"key":"1187_CR64","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1901281","volume":"384","author":"SPRINT Research Group","year":"2021","unstructured":"SPRINT Research Group. Final report of a trial of intensive versus standard blood-pressure control. N. Engl. J. Med. 384, 1921\u20131930 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1187_CR65","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0140-6736(21)01921-8","volume":"398","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration.","year":"2021","unstructured":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet 398, 1053\u20131064 (2021).","journal-title":"Lancet"},{"key":"1187_CR66","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1161\/HYPERTENSIONAHA.124.23597","volume":"81","author":"PK Whelton","year":"2024","unstructured":"Whelton, P. K., O\u2019Connell, S., Mills, K. T. & He, J. Optimal antihypertensive systolic blood pressure: a systematic review and meta-analysis. Hypertension 81, 2329\u20132339 (2024).","journal-title":"Hypertension"},{"key":"1187_CR67","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S0140-6736(22)02603-4","volume":"401","author":"J He","year":"2023","unstructured":"He, J. et al. Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial. Lancet 401, 928\u2013938 (2023).","journal-title":"Lancet"},{"key":"1187_CR68","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1056\/NEJMoa2412006","volume":"392","author":"Y Bi","year":"2025","unstructured":"Bi, Y. et al. Intensive blood-pressure control in patients with type 2 diabetes. N. Engl. J. Med. 392, 1155\u20131167 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1187_CR69","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","volume":"358","author":"NS Beckett","year":"2008","unstructured":"Beckett, N. S. et al. Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 358, 1887\u20131898 (2008).","journal-title":"N. Engl. J. Med."},{"key":"1187_CR70","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1001\/jama.2016.7050","volume":"315","author":"JD Williamson","year":"2016","unstructured":"Williamson, J. D. et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged \u226575 years: a randomized clinical trial. JAMA 315, 2673\u20132682 (2016).","journal-title":"JAMA"},{"key":"1187_CR71","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1161\/CIRCULATIONAHA.123.064003","volume":"148","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. The effect of frailty on the efficacy and safety of intensive blood pressure control: a post hoc analysis of the SPRINT trial. Circulation 148, 565\u2013574 (2023).","journal-title":"Circulation"},{"key":"1187_CR72","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"HH Parving","year":"2012","unstructured":"Parving, H. H. et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 367, 2204\u20132213 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1187_CR73","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.","year":"2002","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 288, 2981\u20132997 (2002).","journal-title":"JAMA"},{"key":"1187_CR74","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","volume":"122","author":"DS Wald","year":"2009","unstructured":"Wald, D. S., Law, M., Morris, J. K., Bestwick, J. P. & Wald, N. J. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am. J. Med. 122, 290\u2013300 (2009).","journal-title":"Am. J. Med."},{"key":"1187_CR75","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006986","volume":"6","author":"TM MacDonald","year":"2017","unstructured":"MacDonald, T. M. et al. Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: a double-blind randomized controlled trial. J. Am. Heart Assoc. 6, e006986 (2017).","journal-title":"J. Am. Heart Assoc."},{"key":"1187_CR76","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1001\/jama.2018.10359","volume":"320","author":"R Webster","year":"2018","unstructured":"Webster, R. et al. Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka: a randomized clinical trial. JAMA 320, 566\u2013579 (2018).","journal-title":"JAMA"},{"key":"1187_CR77","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S0140-6736(21)01922-X","volume":"398","author":"CK Chow","year":"2021","unstructured":"Chow, C. K. et al. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet 398, 1043\u20131052 (2021).","journal-title":"Lancet"},{"key":"1187_CR78","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1161\/HYPERTENSIONAHA.118.11308","volume":"72","author":"F Rea","year":"2018","unstructured":"Rea, F., Corrao, G., Merlino, L. & Mancia, G. Initial antihypertensive treatment strategies and therapeutic inertia. Hypertension 72, 846\u2013853 (2018).","journal-title":"Hypertension"},{"key":"1187_CR79","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1161\/HYPERTENSIONAHA.120.15781","volume":"77","author":"G Parati","year":"2021","unstructured":"Parati, G., Kjeldsen, S., Coca, A., Cushman, W. C. & Wang, J. Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension 77, 692\u2013705 (2021).","journal-title":"Hypertension"},{"key":"1187_CR80","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1097\/HJH.0000000000000222","volume":"32","author":"G Mancia","year":"2014","unstructured":"Mancia, G., Zambon, A., Soranna, D., Merlino, L. & Corrao, G. Factors involved in the discontinuation of antihypertensive drug therapy: an analysis from real life data. J. Hypertens. 32, 1708\u20131715 (2014).","journal-title":"J. Hypertens."},{"key":"1187_CR81","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1097\/HJH.0000000000002523","volume":"38","author":"C Thomopoulos","year":"2020","unstructured":"Thomopoulos, C., Bazoukis, G., Tsioufis, C. & Mancia, G. Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials. J. Hypertens. 38, 1669\u20131681 (2020).","journal-title":"J. Hypertens."},{"key":"1187_CR82","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1097\/HJH.0000000000000614","volume":"33","author":"C Thomopoulos","year":"2015","unstructured":"Thomopoulos, C., Parati, G. & Zanchetti, A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses. J. Hypertens. 33, 1321\u20131341 (2015).","journal-title":"J. Hypertens."},{"key":"1187_CR83","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.21618","volume":"3","author":"J Wei","year":"2020","unstructured":"Wei, J. et al. Comparison of cardiovascular events among users of different classes of antihypertension medications: a systematic review and network meta-analysis. JAMA Netw. Open 3, e1921618 (2020).","journal-title":"JAMA Netw. Open"},{"key":"1187_CR84","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/HJH.0000000000000447","volume":"33","author":"C Thomopoulos","year":"2015","unstructured":"Thomopoulos, C., Parati, G. & Zanchetti, A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs-overview and meta-analyses. J. Hypertens. 33, 195\u2013211 (2015).","journal-title":"J. Hypertens."},{"key":"1187_CR85","doi-asserted-by":"publisher","first-page":"b1665","DOI":"10.1136\/bmj.b1665","volume":"338","author":"MR Law","year":"2009","unstructured":"Law, M. R., Morris, J. K. & Wald, N. J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338, b1665 (2009).","journal-title":"BMJ"},{"key":"1187_CR86","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.mayocp.2018.02.020","volume":"93","author":"FH Messerli","year":"2018","unstructured":"Messerli, F. H., Suter, T. & Bangalore, S. What ever happened to cardioprotection with beta-blockers? Mayo Clin. Proc. 93, 401\u2013403 (2018).","journal-title":"Mayo Clin. Proc."},{"key":"1187_CR87","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1097\/HJH.0b013e3282f4edd7","volume":"26","author":"G Corrao","year":"2008","unstructured":"Corrao, G. et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J. Hypertens. 26, 819\u2013824 (2008).","journal-title":"J. Hypertens."},{"key":"1187_CR88","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2174\/1573402114666180918102735","volume":"15","author":"GT do Vale","year":"2019","unstructured":"do Vale, G. T., Ceron, C. S., Gonzaga, N. A., Simplicio, J. A. & Padovan, J. C. Three generations of beta-blockers: history, class differences and clinical applicability. Curr. Hypertens. Rev. 15, 22\u201331 (2019).","journal-title":"Curr. Hypertens. Rev."},{"key":"1187_CR89","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1097\/HJH.0000000000002382","volume":"38","author":"M Viigimaa","year":"2020","unstructured":"Viigimaa, M. et al. Update of the position paper on arterial hypertension and erectile dysfunction. J. Hypertens. 38, 1220\u20131234 (2020).","journal-title":"J. Hypertens."},{"key":"1187_CR90","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(22)01786-X","volume":"400","author":"IS Mackenzie","year":"2022","unstructured":"Mackenzie, I. S. et al. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet 400, 1417\u20131425 (2022).","journal-title":"Lancet"},{"key":"1187_CR91","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams, B. et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386, 2059\u20132068 (2015).","journal-title":"Lancet"},{"key":"1187_CR92","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1161\/HYPERTENSIONAHA.117.10662","volume":"71","author":"EM Krieger","year":"2018","unstructured":"Krieger, E. M. et al. Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT randomized study (resistant hypertension optimal treatment). Hypertension 71, 681\u2013690 (2018).","journal-title":"Hypertension"},{"key":"1187_CR93","volume":"2","author":"TS Tam","year":"2017","unstructured":"Tam, T. S. et al. Eplerenone for hypertension. Cochrane Database Syst. Rev. 2, CD008996 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1187_CR94","doi-asserted-by":"publisher","first-page":"e467","DOI":"10.4244\/EIJ-D-23-00836","volume":"20","author":"L Lauder","year":"2024","unstructured":"Lauder, L., Kandzari, D. E., L\u00fcscher, T. F. & Mahfoud, F. Renal denervation in the management of hypertension. EuroIntervention 20, e467\u2013e478 (2024).","journal-title":"EuroIntervention"},{"key":"1187_CR95","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/eurheartj\/ehad054","volume":"44","author":"E Barbato","year":"2023","unstructured":"Barbato, E. et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC council on hypertension and the European association of percutaneous cardiovascular interventions (EAPCI). Eur. Heart J. 44, 1313\u20131330 (2023).","journal-title":"Eur. Heart J."},{"key":"1187_CR96","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1161\/CIRCULATIONAHA.124.069709","volume":"150","author":"D Vukadinovic","year":"2024","unstructured":"Vukadinovic, D. et al. Effects of catheter-based renal denervation in hypertension: a systematic review and meta-analysis. Circulation 150, 1599\u20131611 (2024).","journal-title":"Circulation"}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01187-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01187-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01187-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T19:06:25Z","timestamp":1757271985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01187-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":96,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1187"],"URL":"https:\/\/doi.org\/10.1038\/s41569-025-01187-2","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"17 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.L. has received speaker honoraria from AstraZeneca, Medtronic, Pfizer and Recor Medical, and advisory fees from Medtronic and Recor Medical. T.W. has received speaker honoraria and advisory fees from AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Gedeon Richter, Medtronic, Menarini, Merck, Pfizer, Recor and Servier. M.B. has received personal fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Medtronic, Novartis, Recor, Servier and Vifor. S.B. reports speaker\/consulting fees to the department from Amgen, Daiichi Sankyo, Medtronic, Merck, Novartis, Recor Medical, Sanofi and Servier. R.M.B. reports speaker honoraria from El Kendi and Servier, and has received devices on free loan from Quipu, Unex and Visualsonics-Fujifilm. E.G. has received honoraria for a lecture at a seminar from Amgen and Boehringer Ingelheim. R.K. has received honoraria for consultancy, lectures and support for research from AstraZeneca, Bayer, Krka, Menarini Group, Merck, PolPharma, ProMed, Recor, Sanofi and Servier. G.M. has received compensation as a speaker, chairman and\/or consultant from Berlin Chemie, IPCA Laboratories, Medtronic, Menarini, Merck Healthcare, Omnicuris, Recordati, Sanofi, Servier and Sun Laboratories. R.J.M. has received institutional payments for licensing and consulting from Omron concerning a telemonitoring system. G.P. has received speaker honoraria from Merck, Omron, Somnomedics and Viatris. R.d.P. has received speaker honoraria from Merck, Servier and Tecnimede. K.R. has received honoraria to his institution for an advisory role to Medtronic, and has received funding for research from the European Union, Medical Research Council, Novo Nordisk, Roche and UK Research and Innovation. P.S. has received advisory honoraria from Astellas, AstraZeneca, Baxter, Bayer, Boehringer Ingelheim, Healthink, Menarini, Primeview and Recor Medical, and has received speaker honoraria from AICME, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Genesis Pharma, Menarini, Peervoice, Science Collected, Springer and WebMD, and has received institutional research support from Boehringer Ingelheim, Genesis Pharma, Menarini and Vianex. A.E.S. has received speaker honoraria from Abbott, Aktiia, AstraZeneca, Medtronic, Omron, Sanofi and Servier, and serves on scientific advisory boards for Medtronic, SiSU Health and Sky Labs. B.W. is the Chief Scientific and Medical Officer at the British Heart Foundation, chairs and\/or serves on the scientific steering committees of clinical trials of currently unlicensed new medicines supported by Alnylam, AstraZeneca and Novartis, and has provided scientific advice to Anlia and Eli Lilly. F.M. has received speaker honoraria\/consulting fees from Ablative Solutions, AstraZeneca, Inari, Medtronic, Merck, Novartis, Philips and Recor Medical, and Saarland University has received scientific support from Ablative Solutions, Medtronic and Recor Medical. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}